Form 4: Vistagen Therapeutics Director Ann Cunningham Granted Stock Options

Director Ann Michelle Cunningham of Vistagen Therapeutics, Inc. was granted stock options on March 4, 2024, according to a Form 4 filing with the SEC.

Summary

• Ann Michelle Cunningham, a director of Vistagen Therapeutics, Inc., was granted 12,500 stock options on March 4, 2024.
• The options have an exercise price of $4.85 and expire on March 4, 2034.
• The options vest in twelve equal monthly installments, beginning on the grant date.
• A Power of Attorney was executed on September 7, 2023, granting Shawn K. Singh and Cynthia Anderson the authority to file Forms 3, 4, and 5 on behalf of Ann Cunningham.

Sentiment

Score: 7

Explanation: The document reflects a standard corporate action (granting of stock options) which is generally viewed neutrally to positively as it aligns director interests with shareholders. The sentiment is slightly positive due to the incentive provided to the director.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders by incentivizing them to increase the company's stock price.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of twelve equal monthly installments is a relatively common practice, designed to retain key personnel.
• The exercise price of $4.85 would need to be compared to the market price of VTGN stock at the time of the grant to determine if it is at, above, or below market value, which is a standard practice.
• Comparable companies in the biotech space, such as Biohaven or Axsome Therapeutics, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the granting of stock options positively as it aligns the director's interests with increasing shareholder value.
• The director benefits from the potential to profit from an increase in the company's stock price.

Key Dates